Ahmed Awad, DO
Nephrology · Kansas City, MONPI 1740245182
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $65,017 of the $78,929 with a category attached, or 82.4%. 33 manufacturers reported payments, led by Johnson & Johnson at 54.7% of the total. Reporting peaked in 2019 at $30,064 and has fallen 76.7% since, to $7,013 in 2025. Among nephrology clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 270 payments — averaging $292.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$43K
- Bayer$10K
- Amgen$7K
- Akebia Therapeutics Inc$6K
- Vifor Pharma, Inc.$4K
- AstraZeneca$4K
- plus $5K from 27 others
Across 3,284 payments — averaging $3747.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$6.1M
- Akebia Therapeutics Inc$1.4M
- AstraZeneca$1.2M
- Bayer$878K
- Boehringer Ingelheim$639K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$401K
- plus $1.6M from 23 others
What the payments were for
- Consulting fees$1,0981%
- Speaking & faculty fees$65,01782%
- Travel & lodging$5,4017%
- Food & beverage$7,0249%
- Education$3890%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 33 | $43,168 |
| Bayer | 20 | $9,813 |
| Amgen(2 entities) | 36 | $7,174 |
| Akebia Therapeutics Inc | 30 | $5,959 |
| Vifor Pharma, Inc. | 14 | $4,398 |
| AstraZeneca(2 entities) | 28 | $3,914 |
| Otsuka America Pharmaceutical, Inc. | 8 | $1,367 |
| Mallinckrodt Hospital Products Inc. | 9 | $487 |
| OPKO Pharmaceuticals, LLC | 22 | $424 |
| Novartis | 11 | $378 |
| Novo Nordisk | 9 | $293 |
| Medtronic | 1 | $157 |
| Travere Therapeutics, Inc. | 8 | $142 |
| Astrazeneca UK Limited | 1 | $135 |
| Covidien LP | 1 | $119 |
| Boehringer Ingelheim | 6 | $112 |
| Calliditas Therapeutics US Inc. | 4 | $103 |
| Nxstage Medical, Inc. | 1 | $88 |
| Daiichi Sankyo Inc. | 4 | $81 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $77 |
| GSK | 3 | $74 |
| Apellis Pharmaceuticals, Inc. | 3 | $72 |
| Sanofi | 3 | $68 |
| Bard Peripheral Vascular, Inc. | 2 | $65 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $44 |
| ANI Pharmaceuticals, Inc. | 2 | $44 |
| Invivyd Inc | 1 | $34 |
| Mallinckrodt Enterprises LLC | 1 | $34 |
| Cormedix Inc. | 1 | $29 |
| Ardelyx, Inc. | 1 | $21 |
| Kyowa Kirin, Inc. | 1 | $20 |
| Amicus Therapeutics, Inc. | 1 | $19 |
| Aurinia Pharma U.S., Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$78,929 in reported general payments places this provider in the 95th percentile of 253 nephrology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VeltassaPatiromer Calcium Sorbitex | 31 | $35,778 |
| FarxigaDapagliflozin Propanediol | 32 | $31,189 |
| JardianceEmpagliflozin | 30 | $23,921 |
| RayaldeeCalcifediol | 12 | $15,891 |
| KerendiaFinerenone | 11 | $9,280 |
| Sevelamer Carbonate | 35 | $7,638 |
| EliquisApixaban | 11 | $6,579 |
| Calcium Acetate | 25 | $1,890 |
| SynthroidLevothyroxine Sodium | 11 | $1,467 |
| Amlodipine Besylate | 150 | $1,245 |
| Tacrolimus | 23 | $696 |
| Nifedipine ErNifedipine | 13 | $659 |
| Gabapentin | 67 | $643 |
| Carvedilol | 101 | $614 |
| Pantoprazole Sodium | 58 | $608 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $3,914 | $31,18932 claims |
| Boehringer IngelheimJardiance | $112 | $23,92130 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $424 | $15,89112 claims |
| BayerKerendia | $9,813 | $9,28011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 253 nephrology providers in Missouri.
Other nephrology in Kansas City
- Richard CaplingKansas City$31K
- Tarek DarwishKansas City$8K
- Jignesh ShahKansas City$7K
- Adnan KhanKansas City$7K
- Robert GolderKansas City$5K
- Archana GoelKansas City$5K
- Ryan LustigKansas City$4K
- Pranavkumar DalalKansas City$4K
- Rafael TorosyanKansas City$3K
- Derek LarsonCreve Coeur$605K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.